We’re starting to understand more that endometrial cancer harbors a number of cell surface markers, including folate receptor ...

A panelist discusses how folate receptor alpha (FRα) expression testing plays a crucial role in determining eligibility for mirvetuximab soravtansine (an antibody-drug conjugate therapy), emphasizing ...

Mirvetuximab soravtansine-gynx (Elahere) received full FDA approval for the treatment of folate receptor alpha–positive (FRα+), platinum-resistant ovarian cancer (PROC) based on findings from the ...

In this video, Ursula A. Matulonis, MD, discusses new data on rinatabart sesutecan, or Rina-S, for patients with advanced ovarian cancer, which were presented at Society of Gynecologic Oncology Annual ...

The Food and Drug Administration has set priority review for Elahrere as use of treatment in patients with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, ...

Sarasota Memorial Hospital is conducting a clinical trial for a new ovarian cancer drug, Mirvetuximab Soravtansine. The drug targets the protein folate receptor-alpha, often found in high levels in ...

A comparative study of the real-world safety and effectiveness of metronomic cyclophosphamide and bevacizumab with or without pembrolizumab for recurrent ovarian cancer. This is an ASCO Meeting ...

A pooled analysis of JSKN003, a biparatopic anti-HER2 antibody conjugate (ADC), in patients with advanced HER2-overexpressing (IHC 3+) gastrointestinal tumors. This is an ASCO Meeting Abstract from ...